Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. A mid-atlantic oncology program study

✍ Scribed by Harvey Rothman; James E. Cantrell; Jacob Lokich; Santo Difino; Jimmie Harvey; James Ahlgren; John Fryer

• Publisher: John Wiley and Sons
• Year: 1991
• Tongue: English
• Weight: 450 KB
• Volume: 68
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19910715)68:2<264::aid-cncr2820680208>3.0.co;2-5

✦ Synopsis

Fifty-six previously untreated patients with biopsy-proven, locally advanced or metastatic and measurable adenocarcinoma of the pancreas were treated with the combination of a protracted intravenous infusion of 5-fluorouracil (5-FU) and low dose weekly bolus cisplatin administered continuously for 10 weeks followed by a %week rest period. The objective response rate was 16% with two patients (4%) achieving a complete response (confidence intervals, 8% to 29%). The median survival time for all treated patients was 5.8 months; however, 26% of all patients were alive at 1 year. Both median survival time and the proportion alive at 1 year exceed that of prior reports involving large patient groups, possibly due to better patient selection.